Novozymes A/S Stock Forecast, Price & News

+1.21 (+1.80 %)
(As of 04/22/2021 12:00 AM ET)
Today's Range
Now: $68.35
50-Day Range
MA: $63.96
52-Week Range
Now: $68.35
Volume17,366 shs
Average Volume13,586 shs
Market Capitalization$15.81 billion
P/E Ratio41.68
Dividend Yield0.83%
Novozymes A/S produces and sells industrial enzymes and microorganisms in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers agriculture solutions, including crop production, and animal health and nutrition solutions; liquefaction, saccharifaction, fermentation, cellulosic hydrolysis, and process enhancement solutions for bioenergy; baking, beverages, dairy, starch, and protein ingredients for the food and beverage industry; and laundry, dishwashing, and professional cleaning solutions for the household care industry. It also provides wastewater solutions, such as additives, biogas production, industrial bio cleaning, compound removal, odor control, and system start-up solutions; and textile solutions comprising denim abrasion and finishing, biopreparation, biopolishing bleach clean-up, and desizing solutions. In addition, the company offers forest products that include bleach boosting, deinking, fiber modification, effluent control, pitch and stickies control, and starch modification products; and leather solutions, which comprise biopreparation, degreasing, and re-bating. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis; and rTrypsin for cell culture. Novozymes A/S has collaboration with FMC Corporation to co-develop enzyme solutions. The company is based in Bagsvaerd, Denmark.
Novozymes A/S logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Year Founded2000



Sales & Book Value

Annual Sales$2.16 billion
Cash Flow$1.86 per share
Book Value$5.79 per share


Net Income$472.79 million


Market Cap$15.81 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableNot Optionable


Novozymes A/S (OTCMKTS:NVZMY) Reaches New 1-Year High at $67.50
April 21, 2021 |  americanbankingnews.com
Reduction of share capital
April 12, 2021 |  finance.yahoo.com
Novozymes A/S’ Annual Shareholders’ Meeting 2021
March 11, 2021 |  finance.yahoo.com
Invitation to Novozymes' annual shareholders' meeting 2021
February 11, 2021 |  finance.yahoo.com
Group financial statement and annual report for 2020
February 2, 2021 |  finance.yahoo.com
Novozymes completes acquisition of Microbiome Labs
January 8, 2021 |  finance.yahoo.com
The Strength Of Family-Run Businesses
December 18, 2020 |  seekingalpha.com
Novozymes acquires Microbiome Labs
December 18, 2020 |  finance.yahoo.com
Novozymes to buy U.S. probiotics maker Microbiome Labs
December 18, 2020 |  finance.yahoo.com
See More Headlines


Overall MarketRank

0.92 out of 5 stars

Basic Materials Sector

380th out of 851 stocks

Biological Products, Except Diagnostic Industry

136th out of 177 stocks

Analyst Opinion: 0.0Community Rank: 1.7Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
+1.21 (+1.80 %)
(As of 04/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVZMY News and Ratings via Email

Sign-up to receive the latest news and ratings for NVZMY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Novozymes A/S (OTCMKTS:NVZMY) Frequently Asked Questions

Is Novozymes A/S a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novozymes A/S in the last year. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Novozymes A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVZMY, but not buy additional shares or sell existing shares.
View analyst ratings for Novozymes A/S
or view top-rated stocks.

What stocks does MarketBeat like better than Novozymes A/S?

Wall Street analysts have given Novozymes A/S a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Novozymes A/S wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Novozymes A/S?

Novozymes A/S saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 14,400 shares, a decline of 30.8% from the March 15th total of 20,800 shares. Based on an average daily volume of 17,900 shares, the short-interest ratio is presently 0.8 days.
View Novozymes A/S's Short Interest

When is Novozymes A/S's next earnings date?

Novozymes A/S is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Novozymes A/S

How were Novozymes A/S's earnings last quarter?

Novozymes A/S (OTCMKTS:NVZMY) issued its earnings results on Tuesday, February, 2nd. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by $0.05. The biotechnology company earned $552.16 million during the quarter, compared to analyst estimates of $550.66 million. Novozymes A/S had a trailing twelve-month return on equity of 28.09% and a net margin of 21.63%.
View Novozymes A/S's earnings history

How has Novozymes A/S's stock price been impacted by Coronavirus?

Novozymes A/S's stock was trading at $45.0314 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVZMY stock has increased by 51.8% and is now trading at $68.35.
View which stocks have been most impacted by COVID-19

How often does Novozymes A/S pay dividends? What is the dividend yield for Novozymes A/S?

Novozymes A/S announced a dividend on Monday, March 1st. Stockholders of record on Monday, March 15th will be paid a dividend of $0.8492 per share on Wednesday, March 31st. This represents a yield of 1.38%. The ex-dividend date of this dividend is Friday, March 12th.
View Novozymes A/S's dividend history

Is Novozymes A/S a good dividend stock?

Novozymes A/S pays an annual dividend of $0.56 per share and currently has a dividend yield of 0.83%. The dividend payout ratio of Novozymes A/S is 33.94%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novozymes A/S will have a dividend payout ratio of 32.37% next year. This indicates that Novozymes A/S will be able to sustain or increase its dividend.
View Novozymes A/S's dividend history.

Who are Novozymes A/S's key executives?

Novozymes A/S's management team includes the following people:
  • Ms. Ester Baiget, Pres & CEO (Age 50, Pay $2.74M) (LinkedIn Profile)
  • Mr. Lars Green M.Sc., MSc, Exec. VP & CFO (Age 54, Pay $1.76M) (LinkedIn Profile)
  • Ms. Graziela Chaluppe dos Santos Malucelli, COO and Exec. VP of Operations, Supply & Quality (Age 48) (LinkedIn Profile)
  • Mr. Tobias Cornelius Bjorklund, Head of Investor Relations
  • Mr. Tue Micheelsen, VP of Global Sales & Marketing
  • Mr. Morten Enggaard Rasmussen, Exec. VP of People, Sustainability & Brand
  • Mr. Pedro Luiz Fernandes, Head of Corp. Affairs & Sustainability - Novozymes Latin America
  • Mr. Anders Lund, Exec. VP of Consumer Biosolutions (Age 48) (LinkedIn Profile)
  • Mr. Sebastian Søderberg, VP and Head of New Bus. Devel. - Incubations & Acquisitions
  • Ms. Tina Sejersgard Fano, Exec. VP of Agriculture & Industrial Biosolutions (Age 52)

Who are some of Novozymes A/S's key competitors?

What is Novozymes A/S's stock symbol?

Novozymes A/S trades on the OTCMKTS under the ticker symbol "NVZMY."

How do I buy shares of Novozymes A/S?

Shares of NVZMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novozymes A/S's stock price today?

One share of NVZMY stock can currently be purchased for approximately $68.35.

How much money does Novozymes A/S make?

Novozymes A/S has a market capitalization of $15.81 billion and generates $2.16 billion in revenue each year. The biotechnology company earns $472.79 million in net income (profit) each year or $1.65 on an earnings per share basis.

How many employees does Novozymes A/S have?

Novozymes A/S employs 5,903 workers across the globe.

Does Novozymes A/S have any subsidiaries?

The following companies are subsidiares of Novozymes A/S: Allopartis, Beta Renewables S.p.A., Delta Biotechnology, Earth BioSciences, Grundejerforeningen Hallas Park, Grundejerforeningen Smørmosen, Iogen Bio-Products, MagnaBioAnalytics LLC, Microbiogen PTY Ltd., Natural Industries, Novozymes (China) Biotechnology Co. Ltd., Novozymes (China) Investment Co. Ltd., Novozymes (Shenyang) Biologicals Co. Ltd., Novozymes (Thailand) Limited, Novozymes Australia Pty. Ltd., Novozymes Belgium BVBA, Novozymes BioAg A/S, Novozymes BioAg Inc., Novozymes BioAg Limited, Novozymes BioAg Productos Para Agricultura Ltda., Novozymes BioAg S.A., Novozymes Bioindustrial A/S, Novozymes Bioindustrial China A/S, Novozymes Biologicals Inc., Novozymes Biopharma DK A/S, Novozymes Blair Inc., Novozymes Canada Limited, Novozymes Deutschland GmbH, Novozymes Enzim Dis Ticaret Ltd., Novozymes France S.A.S, Novozymes Hong Kong Ltd., Novozymes Inc., Novozymes Italia S.r.l., Novozymes Japan Ltd., Novozymes Korea Limited, Novozymes Latin America Ltda., Novozymes Malaysia Sdn. Bhd., Novozymes Mexicana S.A. de C.V., Novozymes Mexico S.A. de C.V., Novozymes Nederland B.V., Novozymes North America Inc., Novozymes RUS LLC, Novozymes Singapore Pte. Ltd., Novozymes South Africa (Pty) Ltd., Novozymes South Asia Pvt. Ltd., Novozymes Spain S.A., Novozymes Sweden AB, Novozymes Switzerland AG, Novozymes Switzerland Holding AG, Novozymes UK Ltd, Novozymes US Inc., OrganoBalance GmbH, Pacific Vet Group-USA, Philom Bios, PrecisionBiotics Group Limited, Qingdao Huayuan Fine Bio-Products, Suzhou Hongda Enzyme Co. Ltd., Sybron Biochemicals, TJ Technologies, and Turfal Indústria e Comércio de Produtos Agrônomicos e Biológicos.

When was Novozymes A/S founded?

Novozymes A/S was founded in 2000.

What is Novozymes A/S's official website?

The official website for Novozymes A/S is www.novozymes.com.

Where are Novozymes A/S's headquarters?

Novozymes A/S is headquartered at Krogshoejvej 36, Bagsvaerd G7, 2880.

How can I contact Novozymes A/S?

Novozymes A/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company can be reached via phone at 45-4446-0000 or via email at [email protected]

This page was last updated on 4/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.